Previous research has consistently reported that AEBP1 is highly expressed in various solid tumors, including gastric cancer, colorectal cancer, breast cancer, oral cancer and papillary thyroid cancer, where it promotes tumor progression, epithelial–mesenchymal transition and therapeutic resistance [21,22,23,24,25,26,27,28,29]. Here, AEBP1 is linked to lip and oral cavity carcinoma.